The role of tumor necrosis factor-<b>α</b> in the development and progression of hepatocellular carcinoma

Lingling ZHU; Yani ZHANG; Tingting SHI; Yang WU; Chun GAO; Xiaohui YU; Yujing HE; Jiucong ZHANG

doi:10.12449/JCH241129

Volume 40 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(11): 2320-2325

PDF( 1143 KB)

The role of tumor necrosis factor-α in the development and progression of hepatocellular carcinoma

DOI: 10.12449/JCH241129

Lingling ZHU^{1, 2},
Yani ZHANG^{1, 2},
Tingting SHI^{1, 2},
Yang WU^{1, 2},
Chun GAO¹,
Xiaohui YU¹,
Yujing HE^{1
,
,
,},
Jiucong ZHANG^{1
,
,
,}

1.
Department of Gastroenterology，The 940 Hospital of Joint Logistic Support Force of PLA，Lanzhou 730050，China
2.
The First Clinical Medical College of Gansu University of Chinese Medicine，Lanzhou 730000，China

Research funding:

Central University Excellent Youth Team Cultivation Project (31920220065);

Gansu Province Health Industry Scientific Research Plan Project Contract (GSWSKY2022-76);

Gansu Planning Project on Science and Technology (23JRRA1673)

More Information

Corresponding author: HE Yujing， heyujing2019@163.com （ORCID： 0009-0000-5577-6867）; ZHANG Jiucong， zhangjiucong@163.com （ORCID： 0000-0003-4006-3033）
Received Date: 2024-01-27
Accepted Date: 2024-03-15
Published Date: 2024-11-25

Abstract

Abstract

Tumor necrosis factor-α （TNF-α） is involved in the regulation of multiple biological processes such as the proliferation， invasion， migration， and chemotherapy resistance of hepatocellular carcinoma （HCC） cells through TNF receptor-mediated signaling pathways. At the same time， TNF-α also plays a role in inducing the apoptosis of HCC cells. Some TNF-α inhibitors have been shown to inhibit the progression of HCC and prolong survival time. At present， the potential mechanism of action of TNF-α in HCC remains unclear， and exploration of the interaction between TNF-α and HCC can help to determine the potential therapeutic targets for HCC. This article summarizes the latest research advances in the mechanism of action of TNF-α in HCC and introduces the possibility of targeting TNF-α as a treatment method for HCC， in order to provide a theoretical basis for the prevention and treatment of liver cancer and drug research and development.
- Carcinoma， Hepatocellular,
- Tumor Necrosis Factor-alpha,
- Signal Transduction,
- Molecular Targeted Therapy

FullText(HTML)

References(50)

References

[1]	CHEN YX, WEN HH, ZHOU C, et al. TNF-α derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt/β‍-catenin pathway in SMMC-7721 hepatocellular carcinoma cells[J]. Exp Cell Res, 2019, 378( 1): 41- 50. DOI: 10.1016/j.yexcr.2019.03.005.
[2]	JANG MK, KIM HS, CHUNG YH. Clinical aspects of tumor necrosis factor-α signaling in hepatocellular carcinoma[J]. Curr Pharm Des, 2014, 20( 17): 2799- 2808. DOI: 10.2174/13816128113199990587.
[3]	TIEGS G, HORST AK. TNF in the liver: Targeting a central player in inflammation[J]. Semin Immunopathol, 2022, 44( 4): 445- 459. DOI: 10.1007/s00281-022-00910-2.
[4]	TSENG WC, LAI HC, HUANG YH, et al. Tumor necrosis factor alpha: Implications of anesthesia on cancers[J]. Cancers, 2023, 15( 3): 739. DOI: 10.3390/cancers15030739.
[5]	LAHA D, GRANT R, MISHRA P, et al. The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment[J]. Front Immunol, 2021, 12: 656908. DOI: 10.3389/fimmu.2021.656908.
[6]	COUSSENS LM, WERB Z. Inflammation and cancer[J]. Nature, 2002, 420( 6917): 860- 867. DOI: 10.1038/nature01322.
[7]	WANG X, LIN Y. Tumor necrosis factor and cancer, buddies or foes?[J]. Acta Pharmacol Sin, 2008, 29( 11): 1275- 1288. DOI: 10.1111/j.1745-7254.2008.00889.x.
[8]	KALLIOLIAS GD, IVASHKIV LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies[J]. Nat Rev Rheumatol, 2016, 12( 1): 49- 62. DOI: 10.1038/nrrheum.2015.169.
[9]	CHEN AY, WOLCHOK JD, BASS AR. TNF in the era of immune checkpoint inhibitors: Friend or foe?[J]. Nat Rev Rheumatol, 2021, 17( 4): 213- 223. DOI: 10.1038/s41584-021-00584-4.
[10]	MERCOGLIANO MF, BRUNI S, MAURO F, et al. Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy[J]. Cancers, 2021, 13( 3): 564. DOI: 10.3390/cancers13030564.
[11]	JING YY, SUN K, LIU WT, et al. Tumor necrosis factor-α promotes hepatocellular carcinogenesis through the activation of hepatic progenitor cells[J]. Cancer Lett, 2018, 434: 22- 32. DOI: 10.1016/j.canlet.2018.07.001.
[12]	YANG X, SHAO CC, DUAN LX, et al. Oncostatin M promotes hepatic progenitor cell activation and hepatocarcinogenesis via macrophage-derived tumor necrosis factor-α[J]. Cancer Lett, 2021, 517: 46- 54. DOI: 10.1016/j.canlet.2021.05.039.
[13]	XIA LM, MO P, HUANG WJ, et al. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis[J]. Carcinogenesis, 2012, 33( 11): 2250- 2259. DOI: 10.1093/carcin/bgs249.
[14]	XU ZW, YAN SX, WU HX, et al. The influence of TNF-α and Ang II on the proliferation, migration and invasion of HepG2 cells by regulating the expression of GRK2[J]. Cancer Chemother Pharmacol, 2017, 79( 4): 747- 758. DOI: 10.1007/s00280-017-3267-z.
[15]	XU ZW, YAN SX, WU HX, et al. Angiotensin II and tumor necrosis factor-α stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression[J]. Dig Liver Dis, 2019, 51( 2): 263- 274. DOI: 10.1016/j.dld.2018.06.007.
[16]	SHI JN, SONG SP, LI SX, et al. TNF-α/NF-κB signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression[J]. Cancer Med, 2021, 10( 10): 3346- 3357. DOI: 10.1002/cam4.3832.
[17]	ZHANG GP, YUE X, LI SQ. Cathepsin C interacts with TNF-α/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma[J]. Cancer Res Treat, 2020, 52( 1): 10- 23. DOI: 10.4143/crt.2019.145.
[18]	ZONG C, MENG Y, YE F, et al. AIF1+CSF1R+MSCs, induced by TNF-α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis[J]. Hepatology, 2023, 78( 2): 434- 451. DOI: 10.1002/hep.32738.
[19]	MENG Y, ZHAO QD, AN LW, et al. A TNFR2-hnRNPK axis promotes primary liver cancer development via activation of YAP signaling in hepatic progenitor cells[J]. Cancer Res, 2021, 81( 11): 3036- 3050. DOI: 10.1158/0008-5472.CAN-20-3175.
[20]	QI DD, LU M, XU PF, et al. Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF-α signaling[J]. Cancer Commun, 2023, 43( 12): 1354- 1372. DOI: 10.1002/cac2.12482.
[21]	LIU ZC, NING F, WANG HF, et al. Epidermal growth factor and tumor necrosis factor α cooperatively promote the motility of hepatocellular carcinoma cell lines via synergistic induction of fibronectin by NF-κB/p65[J]. Biochim Biophys Acta Gen Subj, 2017, 1861( 11 Pt A): 2568- 2582. DOI: 10.1016/j.bbagen.2017.08.010.
[22]	KASTL L, SAUER SW, RUPPERT T, et al. TNF-α mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-κB activation in liver cells[J]. FEBS Lett, 2014, 588( 1): 175- 183. DOI: 10.1016/j.febslet.2013.11.033.
[23]	HUANG BP, LIN CS, WANG CJ, et al. Upregulation of heat shock protein 70 and the differential protein expression induced by tumor necrosis factor-alpha enhances migration and inhibits apoptosis of hepatocellular carcinoma cell HepG2[J]. Int J Med Sci, 2017, 14( 3): 284- 293. DOI: 10.7150/ijms.17861.
[24]	ZHU Y, CHENG Y, GUO YB, et al. Protein kinase D2 contributes to TNF-α-induced epithelial mesenchymal transition and invasion via the PI3K/GSK-3β/β-catenin pathway in hepatocellular carcinoma[J]. Oncotarget, 2016, 7( 5): 5327- 5341. DOI: 10.18632/oncotarget.6633.
[25]	SHRESTHA R, BRIDLE KR, CRAWFORD DHG, et al. TNF-α-mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma[J]. Mol Med Rep, 2020, 21( 4): 1849- 1860. DOI: 10.3892/mmr.2020.10991.
[26]	DASH S, SARASHETTI PM, RAJASHEKAR B, et al. TGF-β2-induced EMT is dampened by inhibition of autophagy and TNF-α treatment[J]. Oncotarget, 2018, 9( 5): 6433- 6449. DOI: 10.18632/oncotarget.23942.
[27]	TAN WL, LUO X, LI WD, et al. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma[J]. EBioMedicine, 2019, 40: 446- 456. DOI: 10.1016/j.ebiom.2018.12.047.
[28]	ZHOU C, SUN BY, ZHOU PY, et al. MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway[J]. Clin Immunol, 2023, 256: 109770. DOI: 10.1016/j.clim.2023.109770.
[29]	LI N, WANG JN, ZHANG N, et al. Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells[J]. Cancer Immunol Immunother, 2018, 67( 2): 271- 283. DOI: 10.1007/s00262-017-2086-8.
[30]	ZHAO L, JIN Y, YANG C, et al. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma[J]. Clin Exp Immunol, 2020, 201( 3): 289- 296. DOI: 10.1111/cei.13470.
[31]	ZHENG XX, CHEN XD, WU WC. The regulatory axis of PD-L1 isoform 2/TNF/T cell proliferation is required for the canonical immune-suppressive effects of PD-L1 isoform 1 in liver cancer[J]. Int J Mol Sci, 2023, 24( 7): 6314. DOI: 10.3390/ijms24076314.
[32]	TOKAY E, SAGKAN RI, KOCKAR F. TNF-α induces URG-4/URGCP gene expression inHepatoma cells through starvation dependent manner[J]. Biochem Genet, 2021, 59( 1): 300- 314. DOI: 10.1007/s10528-020-09972-z.
[33]	KOU XR, JING YY, DENG WJ, et al. Tumor necrosis factor-α attenuates starvation-induced apoptosis through upregulation of ferritin heavy chain in hepatocellular carcinoma cells[J]. BMC Cancer, 2013, 13: 438. DOI: 10.1186/1471-2407-13-438.
[34]	SUN QM, HU B, FU PY, et al. Long non-coding RNA 00607 as a tumor suppressor by modulating NF-κB p65/p53 signaling axis in hepatocellular carcinoma[J]. Carcinogenesis, 2018, 39( 12): 1438- 1446. DOI: 10.1093/carcin/bgy113.
[35]	LI D, FU J, DU M, et al. Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization[J]. Hepatology, 2016, 64( 4): 1105- 1120. DOI: 10.1002/hep.28637.
[36]	HOU JW, ZHAO RC, XIA WY, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis[J]. Nat Cell Biol, 2020, 22( 10): 1264- 1275. DOI: 10.1038/s41556-020-0575-z.
[37]	VERMA HK, MERCHANT N, BHASKAR LVKS. Tumor necrosis factor-alpha gene promoter(TNF-α G-308A) polymorphisms increase the risk of hepatocellular carcinoma in asians: A meta-analysis[J]. Crit Rev Oncog, 2020, 25( 1): 11- 20. DOI: 10.1615/CritRevOncog.2020034846.
[38]	LI HR, WANG YH, ZHANG M, et al. The high expression of TNF-α and NF-κB in tumor microenvironment predicts good prognosis of patients with BCLC-0-B hepatocellular carcinoma[J]. Transl Cancer Res, 2019, 8( 2): 532- 541. DOI: 10.21037/tcr.2019.03.09.
[39]	GUO DD, QIN L, SUN JP, et al. Dynamic changes of cytokine profiles and their correlation with tumor recurrence following thermal ablation in hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2023, 22: 15330338231190644. DOI: 10.1177/15330338231190644.
[40]	LU MY, YEH ML, HUANG CI, et al. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication[J]. World J Gastroenterol, 2022, 28( 1): 140- 153. DOI: 10.3748/wjg.v28.i1.140.
[41]	ZHANG M, HU J, LI HR, et al. High TNF-α and/or p38MAPK expression predicts a favourable prognosis in patients with T₁N₀M₀ hepatocellular carcinoma: An immunohistochemical study[J]. Oncol Lett, 2019, 17( 6): 4948- 4956. DOI: 10.3892/ol.2019.10193.
[42]	IIDA-UENO A, ENOMOTO M, UCHIDA-KOBAYASHI S, et al. Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2018, 82( 5): 857- 864. DOI: 10.1007/s00280-018-3681-x.
[43]	BRENNER D, BLASER H, MAK TW. Regulation of tumour necrosis factor signalling: Live or let die[J]. Nat Rev Immunol, 2015, 15( 6): 362- 374. DOI: 10.1038/nri3834.
[44]	LI W, JIAN YB. Antitumor necrosis factor-α antibodies as a noveltherapy for hepatocellular carcinoma[J]. Exp Ther Med, 2018, 16( 2): 529- 536. DOI: 10.3892/etm.2018.6235.
[45]	LI K, LI XH, WU ZJ, et al. Adenovirus encoding XAF-1 and TNF-α in the same open reading frame efficiently inhibits hepatocellular cancer cells[J]. Mol Med Rep, 2016, 13( 6): 5169- 5176. DOI: 10.3892/mmr.2016.5193.
[46]	WANG HM, LIU JM, HU XM, et al. Prognostic and therapeutic values of tumor necrosis factor-alpha in hepatocellular carcinoma[J]. Med Sci Monit, 2016, 22: 3694- 3704. DOI: 10.12659/msm.899773.
[47]	WANG MD, WU MC, YANG T. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma[J]. EBioMedicine, 2019, 40: 11- 12. DOI: 10.1016/j.ebiom.2019.01.007.
[48]	LEONE GM, MANGANO K, PETRALIA MC, et al. Past, present and(foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12( 4): 1630. DOI: 10.3390/jcm12041630.
[49]	BAI L, WANG K. Research progress of immune-related adverse reactions caused by immune checkpoint inhibitors[J]. J Changchun Univ Chin Med, 2023, 39( 2): 229- 236. DOI: 10.13463/j.cnki.cczyy.2023.02.025. 白黎, 王珂. 免疫检查点抑制剂导致免疫相关不良反应的研究进展[J]. 长春中医药大学学报, 2023, 39( 2): 229- 236. DOI: 10.13463/j.cnki.cczyy.2023.02.025.
[50]	FISCHER R, KONTERMANN RE, PFIZENMAIER K. Selective targeting of TNF receptors as a novel therapeutic approach[J]. Front Cell Dev Biol, 2020, 8: 401. DOI: 10.3389/fcell.2020.00401.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (114) PDF downloads(17)

The role of tumor necrosis factor-α in the development and progression of hepatocellular carcinoma

DOI: 10.12449/JCH241129

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The role of tumor necrosis factor-α in the development and progression of hepatocellular carcinoma

DOI: 10.12449/JCH241129

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content